Candidate Biomarkers for Type 1 Diabetes

Battelle Number(s): 15746; 30002

Patent(s) Issued
Available for licensing in all fields

SUMMARY

Researchers at PNNL have discovered a new method for potentially predicting the onset of type 1 diabetes with more consistency. Until now, the best method for predicting who will develop this disease has been through the identification of three specific autoantibodies produced by the human body against the pancreas, the organ that produces insulin.

As an alternative to that method, researchers have identified a specific set of proteins, together or as individuals, that may provide the same early precursor information. With more development, scientists believe that these proteins may hold the key to earlier detection of type 1 onset and therefore earlier intervention, as well as lead to improved therapies to aid physicians and patients in the management of high blood-glucose levels.

ADVANTAGES

- Potential for dramatic improvement in the consistency of onset determinations
- Information could provide drug therapy companies with insight for better treatments

RELATED LINKS

- "Centers for Disease Controls and Prevention - Diabetes Projects"
- "EMSL Highlights: New Biomarkers Could Mean Better Screening for Type 1 Diabetes"

PATENTS & INTELLECTUAL PROPERTY

- 8,748,352
TECHNOLOGY PORTFOLIO(S)

- Biomedical

POTENTIAL INDUSTRY APPLICATION(S)

- Healthcare, Pharma, Biotech & Medical

CONTACT

**Jennifer J. Lee**
Pacific Northwest National Laboratory
(509) 372-6960
jennifer.lee@pnnl.gov
https://availabletechnologies.pnnl.gov